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Abstract: Background: Coronavirus disease (COVID-19) has affected people’s lives globally. While
important research has been conducted, much remains to be known. In Bangladesh, initial treatment
(self-administered, hospitalized), persistent COVID-19 symptoms (“long COVID-19”), and whether
COVID-19 leads to changes in mental state, such as depressive symptoms, of people are not known.
This study aimed to examine treatment, persistent symptoms, and depression in people who had been
infected with COVID-19 in Bangladesh. Methods: A cross-sectional survey was conducted on 1002 in-
dividuals infected with COVID-19 (60% male; mean age = 34.7 ± 13.9; age range = 18–81 years),
with data taken over a one-month period (11 September 2020 to 13 October 2020). A self-reported
online questionnaire was used to collect data on socio-demographics, lifestyle, COVID-19 symptoms
(during and beyond COVID-19), medication (over-the-counter or doctor-prescribed), and depression
(assessed using the Patient Health Questionnaire (PHQ-9)). Results: Twenty-four percent of partici-
pants self-medicated with over-the-counter medicine when they were first diagnosed with COVID-19.
Self-medication was higher among female vs. male respondents (29.6% vs. 20.2%, respectively,
p = 0.002). A minority (20%) reported that they experienced persistent COVID-like symptoms after
recovering from COVID-19. The most reported persistent symptoms were diarrhea (12.7%) and
fatigue (11.5%). Forty-eight percent of participants were categorized as having moderate to severe
depression. Based on multivariate regression analysis, depression during COVID-19 was positively
associated with lower family income, poor health status, sleep disturbance, lack of physical activity,
hypertension, asthma/respiratory problems, fear of COVID-19 re-infection, and persistent COVID-19
symptoms. Conclusions: The findings suggest a need for appropriate interventions for COVID-19
patients to promote physical and mental wellbeing.
Keywords: depression; COVID-19; severe acute respiratory syndrome coronavirus 2; recovery;
Bangladesh; sleep–wake disorders
1. Introduction
After emerging in December 2019, the novel coronavirus SARS-CoV-2 (severe acute
respiratory syndrome coronavirus 2) has had a significant impact on people globally, and
the number of coronavirus disease (COVID-19) cases continues to increase. Almost all
countries in the world have been affected by the coronavirus, with 98.85 million confirmed
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cases, including 2.12 million deaths, as of 13 January 2021 [1]. At the initial stage, most
cases were suspected of having emerged from zoonotic exposure in Wuhan, China, and
the virus has since been frequently transmitted from human to human, as it has a higher
reproductive capacity than many other infectious diseases [2,3].
According to Bangladesh’s Institute of Epidemiology Disease Control and Research,
the country confirmed its first case on 8 March 2020 [4–6]. Like other countries, Bangladesh
adopted non-therapeutic measures to mitigate COVID-19 spread, such as maintaining
spatial distancing, closing non-essential institutions, and not permitting mass gatherings [7].
Despite this, as of 23 January 2021, Bangladesh held the twenty-seventh position globally,
with 531,326 confirmed cases, including 8003 deaths [8].
Over the last few months, millions of people globally have been hospitalized due to
COVID-19 with multiple symptoms, including fever, dry cough, fatigue, diarrhea, dyspnea,
headache, nausea, and vomiting [9]. Recovery is often not total. In Italy, only 13% of
people were completely free of COVID-19 symptoms after 60 days, with 55% of people
experiencing at least three persistent symptoms and 32% of people experiencing one or
two persistent symptoms [10]. In the USA, COVID-19 patients with persistent symptoms
reported experiencing a lower quality of life after two or three weeks [11]. Following the
outbreak of the previous SARS virus, a chronic post-SARS syndrome was reported one year
after infection [12], affecting people both physically and mentally [13]. Other studies of the
SARS epidemic reported psychiatric concerns after the early recovery phase, reflected in
increased anxiety and depression [14,15].
Self-medication is commonly performed globally. Over-the-counter medicines without a
doctor’s prescription may negatively affect healthcare resources and patients’ health [16–18].
Factors that have been shown to influence self-medication include previous experience
with a disease or a symptom, availability of medicine, increasing costs of prescription
drugs, and the willingness of people to empower themselves [19,20]. In Bangladesh, self-
medication is influenced largely by socioeconomic status, educational attainment, and lack
of proper knowledge [21]. Although the World Health Organization (WHO) advocates
self-medication for inhibiting and treating minor health problems at minimal cost, in severe
cases, it may lead to adverse health outcomes, including higher mortality [22]. The current
doctor-to-patient ratio in Bangladesh is 5.26 to 10,000, placing the country in the second-
lowest position among South Asian countries [23]. Therefore, lack of knowledge, scarcity
of health service resources, new treatment protocols, and unreliable sources of national or
social media news may influence people’s decisions to self-medicate to treat symptoms of
COVID-19, such as fever, sore throat, or dry cough.
Pandemic issues such as spatial distancing, isolation, quarantine, and economic hard-
ships may lead to or exacerbate depression, frustration, fear, grief, anger, shame, desper-
ation, boredom, stress, and panic [6,24–26]. Depression is a relatively common mental
health problem that many individuals will likely experience during and after the crisis [24].
Depression is a significant psychiatric illness affecting more than 264 million people around
the world [27]. Depression affects individuals across the lifespan [28]. Depression is char-
acterized by sadness that may include tearfulness, loss of interest or pleasure, guilt or
low self-worth, trouble sleeping, decreased or increased appetite, low energy, diminished
sex drive, and poor concentration [29]. In Bangladesh, depression has been observed
in different populations during the COVID-19 pandemic, including the general public
(47.2%) [30], university students (62.9%) [26], medical students (49.9%) [31], and healthcare
workers (39.5%) [25]. Previous studies have reported several factors that are associated
with depression, including female sex, living in an urban area, reduced or no physical
exercise, dissatisfaction with sleep, self-reported moderate/poor health status, smoking,
the presence of COVID-19 symptoms, and fear of COVID-19 re-infection [25,26,30,32,33].
A recent study has shown that 56.6% of 153 surveyed COVID-19 patients in Bangladesh
reported depression [34].
To date, no prior study has investigated self-medication, hospitalization, persistent or
ongoing symptoms, and ensuing mental wellbeing in people who were infected with
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COVID-19 in Bangladesh. The correlates of depression and how people respond to
COVID-19 are important to understand given the potential impact of the viral illness
on mood and potential relationships between how people respond to the infection or
recover from it and their health and well-being. Such information may help policy, pre-
vention, and treatment efforts. Thus, this study aimed to explore the characteristics of
people in Bangladesh who were infected by COVID-19. We were interested in under-
standing factors relating to depression, self-medication, hospitalization, and persistence of
COVID-19 symptoms.
2. Materials and Methods
2.1. Participants and Procedure
A cross-sectional survey was conducted over a one-month period (from 11 September
to 13 October 2020) involving people who had previously tested positive for COVID-19 in
Bangladesh. A pre-tested semi-structured questionnaire adapted from the literature [10]
was used to collect data using the Google survey tool. The questionnaire was translated
using the guidelines of back translation (e.g., Beaton et al. (2000)) [35], as previously used
in Bangladesh [25,36,37]. The questionnaire was translated into Bangla (participants’ first
language) and then translated back to English by experts with very good command of
both the Bangla and English languages. A pilot test was conducted on 15 individuals
to assess the questionnaire in terms of acceptability and clarity. Minor modifications
were incorporated after the pilot. Individuals who had recovered from COVID-19 were
then invited to complete the survey. Word-of-mouth and snowballing techniques were
used to recruit participants. Initially, nearly 100 research assistants (RAs) were recruited
from websites and social media through advertisements. Then, they (RAs) were properly
instructed to share our survey link among their family members, friends, colleagues, and
other peers who had recovered from COVID-19. This technique has been used in previous
research in Bangladesh [31]. Approximately 1200 individuals were invited to participate
in the survey, of whom 1083 individuals took part. After removing incomplete surveys,
1002 participants were included in the final sample.
The inclusion criteria of the participants were as follows: ≥18 years old, having tested
positive for COVID-19, and willingness to complete the survey. Exclusion criteria included
having incomplete responses, responses from those who were not infected with COVID-19,
and those who did not consent.
2.2. Sampling Method
The sample size was calculated using the following equation:
n = (z2pq)/d2; n = {1.962 × 0.5 × (1 − 0.5)}/0.052 = 384.16 ≈ 384 (1)
where n = number of samples; z = 1.96 (95% confidence level); p = prevalence estimate (0.5);
q = (1 − p); d = precision limit or proportion of sampling error (0.05).
As there had been no prior similar study focusing on individuals after recovery from
acute COVID-19, we made a best estimate that 50% of the subjects would have psychologi-
cal problems. Assuming a 10% non-response rate, a sample size of 423.5 ≈ 424 participants
was estimated. Our sample size exceeded this estimate.
2.3. Ethics
All procedures were conducted in accordance with the principle for human investi-
gations (i.e., Helsinki Declaration). Formal ethical approval was granted by the Ethical
Review Committee, Uttara Adhunik Medical College (Ref. no: UAMC/ERC/23/2020).
Participants were informed about the procedure and purpose of the study and the confi-
dentiality of the information provided. All participants consented willingly to participate.
All data were collected anonymously and analyzed using a coding system.
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2.4. Measures
The self-report survey consisted of several sections: (i) socio-demographic and lifestyle
information; (ii) health status, underlying health diseases, and COVID-19-related ques-
tions, including questions regarding persistent symptoms; (iii) treatment, including self-
medication and hospitalization; (iv) a psychometric measure of depression using the
Patient Health Questionnaire (PHQ-9) scale; and (v) an assessment of fear of COVID-19
re-infection.
2.4.1. Socio-Demographic and Lifestyle Information
Socio-demographic information obtained included age (later categorized into younger
adults (18–39 years) and middle-aged/older adults (>40 years)), sex (male/female), height,
weight, marital status (unmarried/married/divorced or widowed), family type (nuclear
(two parents and their children)/joint (family unit with more than two parents, extended
family)), monthly family income and residence (urban/rural). Socio-economic status
(SES) was categorized into three classes: lower, middle, and upper, based on monthly
family income (later categorized as lower (<15,000 Bangladeshi Taka (BDT) ≈ 177 US$);
middle (15,000–30,000 BDT ≈ 177–354 US$); and upper (>30,000 BDT ≈ 354 US$)) [38,39].
Body mass index (BMI) was calculated as the ratio of weight in kilograms (kg) to the
square of height in meters (m2). BMI was used to categorize participants as underweight
(<18.5 kg/m2), lean (18.5–24.9 kg/m2), or overweight/obese (>25 kg/m2) [40–42].
Lifestyle-related questions assessing physical activity and smoking were asked with
binary ‘yes/no’ responses. The average number of hours of sleep during the COVID-19
pandemic was obtained through three possible responses: normal (7–9 h), less than average
(<7 h), or more than average (>9 h) [26,43]. For analysis, less than average (<7 h), and more
than average (>9 h) sleep hours were classified as sleep disturbances.
2.4.2. COVID-19 Symptoms and Initial Treatment Measures
Self-reported health status was later categorized as good and moderate/poor (“mod-
erate” and “not good”). Participants also used ‘yes/no’ questions to indicate whether they
suffered from any underlying chronic diseases (diabetes, hypertension, heart problems,
cancer, kidney disease, asthma/respiratory problems).
Data were also obtained using ‘yes/no’ responses to determine the type of COVID-
like symptoms (e.g., fever, fatigue, cough, headache, lack of appetite, sore throat, myalgia,
dyspnea, sputum production, chest pain, and/or diarrhea) both during and after the
COVID-19 stage.
2.4.3. Treatment, Including Self-Medication and Hospitalization
Participants were asked whether they were hospitalized due to COVID-19. Informa-
tion on self-medication was ascertained using a question, “Did you take any medication for
COVID-19 symptoms?”, with three possible answers: treatment from doctor, self-medication,
and no action (rest). Reasons for self-medication were also ascertained.
2.4.4. Patient Health Questionnaire (PHQ-9) Scale
To ascertain the level of depressive symptoms, a validated Bangla version of the
PHQ-9 [44] was used [45,46]. The PHQ-9 consists of nine-item questions on sleep, exhaus-
tion, changes in appetite, difficulties with concentration, and suicidal thoughts over the
past two weeks. An example question is “Do you have trouble falling or staying asleep, or
sleeping too much?”, with a four-point Likert scale ranging from 0 (“Not at all”) to 3 (“Nearly
every day”) [47]. The total score was calculated by summing the raw scores of each item
ranging from 0–27, with a higher score indicating greater severity of depression. The levels
of depressive symptoms were classified into five groups according to their score as minimal
(0–4), mild (5–9), moderate (10–14), moderately severe (15–19), and severe (20–27). In the
present study, the PHQ-9 scale was found to have Cronbach’s α of 0.86.
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2.4.5. Fear of COVID-19 Re-Infection
Participants were asked, using yes/no questions, whether they were worried about re-
infection with COVID-19 (e.g., “Do you fear that you might get infected with COVID-19 again?”).
2.5. Statistical Analyses
Descriptive statistics (e.g., frequencies, percentages, means, standard deviations) and
some first-order analyses (e.g., Chi-square tests, Fisher’s exact tests) were performed.
Variables that significantly differed in bivariate analysis were included in multivariate
regression analysis. Bonferroni-corrected p-values (p < 0.003) were used to determine
statistical significance. All data were analyzed using two statistical software packages
(Microsoft Excel 2019 (Microsoft Corporation, Albuquerque, NM, USA) and IBM SPSS
Statistics version 25 (Armonk, NY, USA)).
3. Results
3.1. Participants
The present sample included 1002 participants with a mean age of 34.7 years (SD = 13.9),
with age ranging from 18–81 years. Table 1 provides data from participants who reported a
confirmed test for COVID-19.
Table 1. Characteristics of people who were infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)





χ2 AOR (95% CI)




(18–39 years) 653 (65.2) 355 (54.4) 298 (45.6) 4.58
Middle-aged/older adults
(>40 years) 349 (34.8) 165 (47.3) 184 (52.7)
Sex
Male 580 (57.9) 191 (45.3) 231 (54.7) 12.86 **
Female 422 (42.1) 329 (56.7) 251 (43.3)
Marital status
Unmarried 436 (43.5) 242 (45.5) 290 (54.5) 19.88 **
Married 532 (53.1) 17 (50.0) 17 (50.0)
Divorced/widowed 34 (3.4) 261 (59.9) 175 (40.1)
Family type ‡
-Nuclear 711 (71.0) 132 (45.4) 159 (54.6) 7.02
Joint 291 (29.0) 388 (54.6) 323 (45.4)
Socioeconomic status (SES)
Lower 259 (25.8) 91 (35.1) 168 (64.9) 55.34 ** 2.22 ** (1.51–3.26)
Middle 345 (34.4) 172 (49.9) 173 (50.1) 1.82 ** (1.3–2.55)
Upper 398 (39.7) 257 (64.6) 141 (35.4) Reference
Health status
Moderate/poor 532 (53.1) 338 (71.9) 132 (28.1) 142.11 ** 3.17 ** (2.33–4.33)
Good 470 (46.9) 182 (34.2) 350 (65.8) Reference
BMI
-Normal/lean 478 (47.7) 31 (62.0) 19 (38.0) 5.21
Underweight 50 (5.0) 230 (48.5) 244 (51.5)
Overweight/obese 474 (47.3) 259 (54.2) 219 (45.8)
Sleep disturbance
Yes 523 (52.2) 216 (41.3) 307 (58.7) 49.20 ** 1.97 ** (1.46–2.64)
No 479 (47.8) 304 (63.5) 175 (36.5) Reference






χ2 AOR (95% CI)
n (%) n (%) n (%)
Smoking
-Yes 123 (12.3) 62 (50.4) 61 (49.6) 0.13
No 879 (87.7) 458 (52.1) 421 (47.9)
Physical exercise
Yes 279 (27.8) 343 (47.4) 380 (52.6) 20.64 **
No 723 (72.2) 177 (63.4) 102 (36.6)
Diabetes
Yes 211 (21.1) 76 (36.0) 135 (64.0) 26.99 **
No 791 (78.9) 444 (56.1) 347 (43.9)
Hypertension/high blood
pressure
Yes 249 (24.9) 101 (40.6) 148 (59.4) 17.05 **
No 753 (75.1) 419 (55.6) 334 (44.4)
Heart disease
Yes 82 (8.2) 28 (34.1) 54 (65.9) 11.27 *
No 920 (91.8) 492 (53.5) 428 (46.5)
Cancer
Yes 24 (2.4) 5 (20.8) 19 (79.2) 9.50 *
No 978 (97.6) 515 (52.7) 463 (47.3)
Kidney problems
-Yes 59 (5.9) 29 (49.2) 30 (50.8) 0.19
No 943 (94.1) 491 (52.1) 452 (47.9)
Asthma/respiratory
problems
Yes 255 (25.4) 98 (38.4) 157 (61.6) 24.84 ** 1.73 * (1.23–2.43)
No 747 (74.6) 422 (56.5) 325 (43.5) Reference
Fear of re-infection
Yes 629 (62.8) 254 (40.4) 375 (59.6) 89.74 ** 2.16 ** (1.58–2.97)
No 373 (37.2) 266 (71.3) 107 (28.7) Reference
Self-medication
Yes 242 (24.2) 104 (43.0) 138 (57.0) 10.17 *
No 760 (75.8) 416 (54.7) 344 (45.3)
Persistent symptoms
Yes 200 (20.0) 59 (29.5) 141 (70.5) 50.21 **
No 802 (80.0) 461 (57.5) 341 (42.5)
Hospitalization
Yes 208 (20.8) 78 (37.5) 130 (62.5) 21.79 **
No 794 (79.2) 442 (55.7) 352 (44.3)
AOR: adjusted odds ratio; CI: confidence interval; BMI: body mass index. † Positive depression indicates moderate to severe depression
(Patient Health Questionnaire (PHQ-9) ≥ 10); ‡ Nuclear (two parents and their children)/ joint (family unit with more than two parents,
extended family); * p < 0.003, ** p < 0.001.
Study participants were characterized by the following attributes: relatively younger
age (<40 years) (65.2%), male (57.9%), married (53.1%), from nuclear families (71.0%), and
lean (47.7%) and overweight/obese (47.3%) BMIs. More than half of the participants expe-
rienced sleep disturbances (52.2%), and most did not engage in physical exercise (72.2%)
during the COVID-19 pandemic. Approximately one-eighth (12.3%) of participants smoked.
Participants reported the following conditions: diabetes (21.1%), hypertension (24.9%),
heart disease (8.2%), cancer (2.4%), kidney problems (5.9%), and asthma/respiratory prob-
lems (25.4%).
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3.2. Hospitalization Due to COVID-19
Twenty-one percent of individuals reported having been hospitalized due to COVID-19.
Bivariate analysis shows that that hospitalization was significantly higher among middle-
aged/older, female and married individuals, those residing in joint family units and re-
porting self-medication, and those with lower SES, overweight/obesity, sleep disturbances,
chronic underlying diseases (e.g., diabetes, heart disease, cancer, and kidney problems), fear of
COVID-19 re-infection, higher depression scores, and persistent COVID-19 symptoms (Table 2).
Table 2. Bivariate analyses using self-medication, persistent symptoms, and hospitalization as dependent variables.
Variables
Hospitalization Self-Medication Persistent Symptoms
Yes No χ2 Yes No χ2 Yes No χ2
n (%) n (%) n (%) n (%) n (%) n (%)
Age
Younger adults 77 (11.8) 576 (88.2) 91.64 ** 131 (20.1) 522 (79.9) 17.12 ** 103 (15.8) 550 (84.2) 20.57 **
Middle-aged/older
adults 131 (37.5) 218 (62.5) 111 (31.8) 238 (68.2) 97 (27.8) 252 (72.2)
Sex
Male 99 (17.1) 481 (82.9) 11.40 * 117 (20.2) 463 (79.8) 11.90 * 91 (15.7) 489 (84.3) 15.72 **
Female 109 (25.8) 313 (74.2) 125 (29.6) 297 (70.4) 109 (25.8) 313 (74.2)
Marital status
Unmarried 52 (11.9) 384 (88.1) 38.76 ** 98 (22.5) 338 (77.5) 3.46 77 (17.7) 359 (82.3) 2.58
Married 150 (28.2) 382 (71.8) 139 (26.1) 393 (73.9) 116 (21.8) 416 (78.2)
Divorced/widowed 6 (17.6) 28 (82.4) 5 (14.7) 29 (85.3) 7 (20.6) 27 (79.4)
Family type ‡
Nuclear 118 (16.6) 593 (83.4) 25.78 ** 163 (22.9) 548 (77.1) 2.01 121 (17) 590 (83) 13.26 **
Joint 90 (30.9) 201 (69.1) 79 (27.1) 212 (72.9) 79 (27.1) 212 (72.9)
Socioeconomic status
(SES)
Lower 96 (37.1) 163 (62.9) 56.76 ** 101 (39) 158 (61) 42.92 ** 92 (35.5) 167 (64.5) 57.94 **
Middle 49 (14.2) 296 (85.8) 71 (20.6) 274 (79.4) 38 (11) 307 (89)
Upper 63 (15.8) 335 (84.2) 70 (17.6) 328 (82.4) 70 (17.6) 328 (82.4)
Health status
Good 61 (13) 409 (87) 32.57 ** 89 (18.9) 381 (81.1) 13.15 ** 53 (11.3) 417 (88.7) 41.78 **
Moderate/poor 147 (27.6) 385 (72.4) 153 (28.8) 379 (71.2) 147 (27.6) 385 (72.4)
BMI
Normal/lean 73 (15.3) 405 (84.7) 27.33 ** 107 (22.4) 371 (77.6) 2.56 75 (15.7) 403 (84.3) 15.29 **
Underweight 4 (8) 46 (92) 10 (20) 40 (80) 6 (12) 44 (88)
Overweight/obese 131 (27.6) 343 (72.4) 125 (26.4) 349 (73.6) 119 (25.1) 355 (74.9)
Sleep disturbance
Yes 136 (26) 387 (74) 18.30 ** 127 (24.3) 396 (75.7) 0.01 143 (27.3) 380 (72.7) 37.31 **
No 72 (15) 407 (85) 115 (24) 364 (76) 57 (11.9) 422 (88.1)
Smoking
Yes 26 (21.1) 97 (78.9) 0.01 28 (22.8) 95 (77.2) 0.15 26 (21.1) 97 (78.9) 0.12
No 182 (20.7) 697 (79.3) 214 (24.3) 665 (75.7) 174 (19.8) 705 (80.2)
Physical exercise
Yes 58 (20.8) 221 (79.2) <0.001 61 (21.9) 218 (78.1) 1.11 58 (20.8) 221 (79.2) 0.17
No 150 (20.7) 573 (79.3) 181 (25) 542 (75) 142 (19.6) 581 (80.4)
Diabetes
Yes 87 (41.2) 124 (58.8) 68.11 ** 71 (33.6) 140 (66.4) 13.16 ** 72 (34.1) 139 (65.9) 33.56 **
No 121 (15.3) 670 (84.7) 171 (21.6) 620 (78.4) 128 (16.2) 663 (83.8)
Hypertension
Yes 67 (26.9) 182 (73.1) 7.62 54 (21.7) 195 (78.3) 1.10 49 (19.7) 200 (80.3) 0.01
No 141 (18.7) 612 (81.3) 188 (25) 565 (75) 151 (20.1) 602 (79.9)
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Table 2. Cont.
Variables
Hospitalization Self-Medication Persistent Symptoms
Yes No χ2 Yes No χ2 Yes No χ2
n (%) n (%) n (%) n (%) n (%) n (%)
Heart disease
Yes 29 (35.4) 53 (64.6) 11.59 * 31 (37.8) 51 (62.2) 9.09 26 (31.7) 56 (68.3) 7.71
No 179 (19.5) 741 (80.5) 211 (22.9) 709 (77.1) 174 (18.9) 746 (81.1)
Cancer
Yes 14 (58.3) 10 (41.7) 21.11 ** 15 (62.5) 9 (37.5) 19.74 ** 13 (54.2) 11 (45.8) 18.01 **
No 194 (19.8) 784 (80.2) 227 (23.2) 751 (76.8) 187 (19.1) 791 (80.9)
Kidney problems
Yes 23 (39) 36 (61) 12.656 ** 26 (44.1) 33 (55.9) 13.57 ** 20 (33.9) 39 (66.1) 7.62
No 185 (19.6) 758 (80.4) 216 (22.9) 727 (77.1) 180 (19.1) 763 (80.9)
Asthma/respiratory
problems
Yes 59 (23.1) 196 (76.9) 1.18 62 (24.3) 193 (75.7) 0.01 53 (20.8) 202 (79.2) 0.15
No 149 (19.9) 598 (80.1) 180 (24.1) 567 (75.9) 147 (19.7) 600 (80.3)
Fear of re-infection
Yes 165 (26.2) 464 (73.8) 30.78 ** 165 (26.2) 464 (73.8) 3.99 177 (28.1) 452 (71.9) 70.77 **
No 43 (11.5) 330 (88.5) 77 (20.6) 296 (79.4) 23 (6.2) 350 (93.8)
Depression
Negative 78 (15) 442 (85) 21.79 ** 104 (20) 416 (80) 10.17 * 59 (11.3) 461 (88.7) 50.21 **
Positive 130 (27) 352 (73) 138 (28.6) 344 (71.4) 141 (29.3) 341 (70.7)
Hospitalization
Yes 208 (100) 0 (0) — 76 (36.5) 132 (63.5) 21.99 ** 106 (51) 102 (49) 157.91 **
No 0 (0) 794 (100) 166 (20.9) 628 (79.1) 94 (11.8) 700 (88.2)
Self-medication
Yes 76 (31.4) 166 (68.6) 21.99 ** 242 (100) 0 (0) — 85 (35.1) 157 (64.9) 45.92 **
No 132 (17.4) 628 (82.6) 0 (0) 760 (100) 115 (15.1) 645 (84.9)
Persistent symptoms
Yes 106 (53) 94 (47) 157.91 ** 85 (42.5) 115 (57.5) 45.92 ** 200 (100) 0 (0) —
No 102 (12.7) 700 (87.3) 157 (19.6) 645 (80.4) 0 (0) 802 (100)
‡ Nuclear (two parents and their children)/ joint (family unit with more than two parents, extended family); * p < 0.003, ** p < 0.001.
Adjusted logistic regression using only those variables that were significant in bivariate
analysis retained middle-aged/older adult, lower SES, and persistent symptoms as factors
associated with COVID-19 hospitalization (Table 3).
Table 3. Multivariate regression analyses for hospitalization, self-medication, and persistent symptoms showing significant
adjusted odds ratios.
Variables
Hospitalization Self-Medication Persistent Symptoms
AOR (95% CI) AOR (95% CI) AOR (95% CI)
Age
Middle-aged/older adults 2.97 ** (1.85–4.77) - -
Younger adults Reference
Socioeconomic status (SES)
Lower 2.04 * (1.28–3.23) 2.31 ** (1.56–3.41) 0.93 (0.59–1.48)
Middle 0.97 (0.62–1.53) 1.28 (0.88–1.88) 0.45 * (0.28–0.72)
Upper Reference Reference Reference
Fear of re-infection
Yes - - 3.32 ** (2.01–5.47)
No Reference
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Table 3. Cont.
Variables
Hospitalization Self-Medication Persistent Symptoms
AOR (95% CI) AOR (95% CI) AOR (95% CI)
Hospitalization
Yes - - 4.89 ** (3.22–7.44)
No Reference
Self-medication
Yes - - 2.23 ** (1.47–3.37)
No Reference
Persistent symptoms
Yes 4.9 ** (3.19–7.51) 2.14 ** (1.44–3.18) -
No Reference Reference
AOR: adjusted odds ratio; CI: confidence interval; * p < 0.003, ** p < 0.001.
3.3. Self-Medication for COVID-19
Participants’ initial treatment after identifying COVID-19 symptoms included consult-
ing a doctor (67.7%), self-medicating (24.2%), and rest for relief (8.2%). Bivariate analyses
showed the proportion of people who self-medicated was significantly higher among
females, individuals of middle-age/older years and lower SES, those who reported hos-
pitalization, poor health, underlying health conditions (e.g., diabetes, cancer, and kidney
problems), moderate to severe depression, and persistent symptoms (Table 2). Adjusted
multiple regression, using only variables that were significant in bivariate analysis, retained
lower SES and persistent COVID-19 symptoms as variables significantly associated with
self-medication (Table 3).
Supplementary Materials questions around reasons for self-medication or unwilling-
ness to seek healthcare consultation included inadequate local medical services (52.4%),
dissatisfaction with local healthcare services (37.4%), cost of consultation with doctors
(12.5%), perception of illness as being non-threatening (32.9%), lack of time (16.8%), and
lower urgency (24.3%).
3.4. Persistent Symptoms (Long COVID-19)
Twenty percent of participants reported that they experienced persistent and ongoing
COVID-like symptoms. Figure 1 summarizes COVID-19 symptoms during the COVID-19
and post-COVID-19 stages. The most frequently reported symptoms during COVID-19
were fever (89.1%) and fatigue (80.8%). In contrast, participants reported diarrhea (12.7%)
and fatigue (11.5%) as the most frequent persistent symptoms.
The proportion of persistent symptoms was higher among middle-aged/older and
female individuals, those living in joint families, and those reporting lower SES, poor
health status, overweight/obesity, sleep disturbances, chronic underlying diseases (e.g.,
diabetes and cancer), fear of COVID-19 re-infection, and moderate to severe depression; self-
medication and hospitalization were also associated (Table 2). Adjusted multiple regression,
using only variables that were significant in bivariate analyses, retained upper SES, fear
of COVID-19 re-infection, hospitalization, and self-medication as variables significantly
associated with persistent symptoms (Table 3).
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3.5. Depressive Symptoms dur ng COVID-19
As per PHQ-9 designation, depression levels were observed as minimal (30.4%), mild
(21.5%), moderate (24.2%), moderately severe (19.4%), and severe (4.6%). The prevalence
estimate of moderate to severe depression was 48.2%. The proportion of moderate to
vere epression was higher m g f m le and married individuals, those of lower SES,
with moderate/poor he lth, with sl ep disturb ce, not engagi g in physical exercise,
having underlying health conditions (e.g., diabetes, hypertension, heart disease, cancer, and
asthma/respiratory problems), reporting self-medication, having persistent symptoms, with
fear of COVID-19 re-infection, and who were hospitalized. Adjusted multiple regression, using
only variables that were statistically significant in bivariate analysis, retained lower SES, poor
health, sleep disturbances, asthma/respiratory problems, and fear of COVID-19 infection as
factors significantly associated with moderate to severe depression (Table 1).
4. Discussion
In this study, we examined correlates of self-medication, hospitalization, persistent
symptoms, and depression with COVID-19 among hospitalized and non-hospitalized
individuals. More than 50% of respondents reported that their health was not good, with
sleep disturbances and difficulties engaging in physical activity. Additionally, diabetes,
hypertension, and asthma/respiratory problems were among the most frequent chronic
diseases reported by participants.
Twenty-one percent of individuals reported having been hospitalized for COVID-19.
Significant odds ratios (ORs) of hospitalization were associated with middle aged/older
adults (OR = 2.97; 95% CI = 1.85–4.77), lower SES (OR = 2.04; 95% CI = 1.28–3.23), and
persistent symptoms (OR = 4.9; 95% CI = 3.19–7.51). These findings resonate with those
from a study from the Dhaka Medical College regarding COVID-19 [48].
Twenty-four percent of people self-medicated after identifying COVID-19 rather than
seeking consultation during the pandemic. This figure is lower than previous studies
conducted in Bangladesh among patients attending outpatient departments (69.0%) [49]
and undergraduate students (88.0%) [50]. Since our study reflected a greater proportion
of younger adults, the lower rate of self-medication might reflect this demographic vari-
able. Other reasons may include fear of the disease and lack of familiarity with medicines.
Hence, individuals may be more likely to consult with their doctor to avoid compli-
cations. Comparisons with other studies may be challenging as it is possible that the
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medication taken for COVID-19 might be in addition to others they may be taking, and
we did not collect these data. Self-medication was significantly associated with lower
SES (OR = 2.31; 95% CI = 1.56–3.41) and the presence of persistent symptoms (OR = 2.14;
95% CI = 1.44–3.18). Reasons for self-medication included limited access to healthcare facili-
ties (52.4%), costs involved in consultation or hospital fees (12.5%), time constraints (16.8%),
and lower perception of illness (32.9%). Similar reasons have been reported in several
studies conducted in northern England and Australia [51,52] and in low- and middle-
income countries [53,54]. Other studies conducted in Bangladesh, Ethiopia, and Poland
suggest that self-medication practices were influenced by the lower cost of medicine, time
restrictions, whether an illness was considered not to be serious, family size, and religious
beliefs [50,55,56]. The proportion of people impacted by COVID-19 was particularly high
in Bangladesh (particularly Dhaka) during this pandemic [57]. The inappropriate use of an-
timicrobials along with other supplementary medicines, without consulting a doctor, may
increase the possibility of drug–drug interactions, hide symptoms of the COVID-19 disease,
and promote the development of antimicrobial resistance [58–60]. In Bangladesh, there is
evidence of increased resistance to antibiotics, as sales of medicines are not restricted [61].
In the present study, nearly two-thirds of participants (62.8%) reported fear of re-infection
of COVID-19, and 20% experienced persistent symptoms of COVID-19. The most frequently
reported persistent symptoms were diarrhea (12.7%) and fatigue (11.5%) during the post-
COVID-19 stage. Factors associated with persistent symptoms were better SES (OR = 0.45;
95% CI = 0.28–0.72), fear of re-infection (OR = 3.32; 95% CI = 2.01–5.47), self-medication
(OR = 2.23; 95% CI = 1.47–3.37), and hospitalization (OR = 4.89; 95% CI = 3.22–7.44). Per-
sistent symptoms have also been reported in Italy, where 87.4% of people reported at least
one symptom (e.g., asthma, fatigue) after recovery from COVID-19 [10]. A study from the
Netherlands and Belgium also reported fatigue and asthma as the most common symptoms
among non-hospitalized individuals three months after the onset of COVID-19 [62]. In
those who were hospitalized due to COVID-19, persistent symptoms included fatigue, dys-
pnea, memory loss, poor sleep, and concentration difficulties [62]. It is therefore important
that follow-up care be offered to individuals who have been ill with COVID-19 [63].
Our study revealed considerable depression (48%) among people who had been in-
fected with COVID-19. It is possible that some individuals had a previous history of
depression and therefore the data captured might not be due to COVID-19. However, our
data agree with published data on depressive symptoms during COVID-19 in Bangladesh
in the general population (47.2%) [30], healthcare workers (39.5%) [25], and medical stu-
dents (49.9%) [31]. It may not be valid to compare pre-COVID rates of depression, as
cohorts may be different and there could be significant variations in demographic factors
such as age, sex, marital status, and other features. Our findings show positive associ-
ations between depression and lower SES (OR = 2.22; 95% CI = 1.51–3.26), good health
status (OR = 3.17; 95% CI = 2.33–4.33), sleep disturbances (OR = 1.96; 95% CI = 1.46–2.64),
asthma/respiratory problems (OR = 1.73; 95% CI = 1.23–2.43), and fear of COVID-19
re-infection (OR = 2.16; 95% CI = 1.58–2.97). Several previous studies in Bangladesh con-
ducted during the COVID-19 pandemic reported that depression was associated with mod-
erate/poor health status, sleep concerns, chronic diseases, smoking, and fear of COVID-19
re-infection [25,26,30,32,33,64]. Another study also suggested that lower family income
(OR = 2.99, 95% CI = 1.11–8.05), persistent symptoms (OR = 2.63; 95% CI = 1.34–5.17), and
poor social support (OR = 3.13; 95% CI = 1.34–7.30) were significantly associated with
depression [65]. Negative emotions linked to COVID-19 may underlie associations with
depression [66]. Our findings agree with data showing frequent depression, panic, and gen-
eral anxiety disorder in Bangladesh during the COVID-19 pandemic [67,68]. A recent study
suggested that the pandemic and economic recession would have a further negative impact
on people who already suffer from mental illness and substance use disorders [69]. Accord-
ing to the WHO, mental health services have been disrupted by COVID-19 in almost 93%
of countries globally [70], with 130 countries showing reduced access to services related to
mental health [71]. The WHO also states that people with pre-existing mental, neurological,
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and substance use disorders have a high risk of mortality during the pandemic [70]. Some
recent studies of the COVID-19 pandemic and psychological concerns in Bangladesh have
reported high rates of depression among different populations [25,26,30,64].
Limitations
Study limitations should be acknowledged when interpreting findings. First, the
study was cross-sectional and thus cannot determine causality. The findings may not
reflect the impact of COVID-19, especially for depression, which may have developed
prior to the COVID-19 pandemic. Longitudinal studies are needed to determine sequential
relationships. Second, this study used an online self-reporting approach that can be
vulnerable to biases (e.g., social desirability, memory recall). However, compared to offline
and/or face-to-face surveys, anonymous questionnaires may increase veracity of responses.
Our study had a high proportion of younger adults and therefore future larger-scale studies
involving a wider age range are warranted. Additionally, the extent to which the findings
generalize to other populations outside of Bangladesh warrants further investigation
using more sophisticated modeling as described elsewhere [72]. In addition, we did not
determine the time frame for when respondents had been diagnosed with COVID-19 prior
to data collection, and future studies should gather such data.
5. Conclusions
The findings of this study contribute to the literature in terms of initial treatment,
persistent symptoms, and mental health concerns among individuals who were infected
with COVID-19 in Bangladesh. The reports indicate that 12.7% of participants reported
diarrhea (12.7%) and fatigue (11.5%) as the most frequent persistent symptoms (“long
COVID-19”), and nearly half of participants experienced moderate to severe depression.
Moreover, like other studies, the socio-demographic and lifestyle factors of participants
involved in this study were linked to depressive symptoms, most notably lower SES,
moderate/poor health status, trouble sleeping, chronic disease, and smoking. Our find-
ings suggest the need for health education programs and interventions (e.g., depression
screening) for people infected with COVID-19 in Bangladesh. The healthcare authority
should be concerned about the individuals who have recovered from COVID-19 in terms
of providing care to them and monitoring their health (including mental health) after their
recovery from COVID-19. Virtual awareness programs should be considered with a view
to mitigating self-medication practices without consultation. Individuals with persistent
COVID-like symptoms should have consultations with healthcare professionals. Mental
health counseling through e-health may be one approach for treating depression among
people during times of spatial distancing. Our findings provide baseline information that
may help guide healthcare provision and policy.
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